Dronedarone and renal impairment: Evaluation of Spanish postmarketing reports and review of literature

Albert Jesus Figueras Suñe, Mónica Tarapués, Gloria Cereza, Albert Figueras

Producció científica: Contribució a revistaArticle de revisióRecercaAvaluat per experts

2 Cites (Scopus)

Resum

© 2015 Informa UK, Ltd. Background: Renal impairment associated with dronedarone use is hardly known. Our aim is to describe the characteristics of spontaneous reports involving renal adverse reactions with use of dronedarone.Methods: In the Spanish Pharmacovigilance database, reports with renal reactions and dronedarone until May 2014 were retrieved and analyzed. Also, a review of case reports of renal failure and dronedarone was conducted in MEDLINE.Results: Dronedarone was found as a suspected drug in 192 reports, 10 (5.2%) of these reports described renal reactions. Renal reactions appeared until 3 months after the onset of dronedarone treatment. In 5 out of 10 cases, dronedarone was withdrawn and the patient recovered. The Reporting Odds Ratio was 2.88 [95% CI 1.52-5.46; p < 0.05]. Additionally, eight cases were found in the medical literature. In five of them, the patient outcome was described as recovered. One patient had to undergo hemodialysis for the treatment of their renal impairment.Conclusions: The effect of dronedarone on the renal function is supported by limited information; therefore, the cases from spontaneous reporting system and those from the medical literature could give relevant additional information. Our analysis shows a potential relationship between dronedarone use and renal impairment. Further studies are needed to confirm these findings.
Idioma originalAnglès
Pàgines (de-a)807-813
RevistaExpert Opinion on Drug Safety
Volum14
Número6
DOIs
Estat de la publicacióPublicada - 1 de juny 2015

Fingerprint

Navegar pels temes de recerca de 'Dronedarone and renal impairment: Evaluation of Spanish postmarketing reports and review of literature'. Junts formen un fingerprint únic.

Com citar-ho